Metabolic dysfunction-associated steatotic liver disease-associated fibrosis and cardiac dysfunction in patients with type 2 diabetes

Figure 1 Association of metabolic dysfunction-associated steatotic liver disease-fibrosis categories with indicators of cardiac dysfunction and dyskinesia. A: Ejection fraction (%) according to the liver fibrosis categories in type 2 diabetes mellitus patients with metabolic dysfunction-associated steatotic liver disease; B: Proportion of patients with an ejection fraction (EF) ≥ 50% (normal), EF = 40%-49% (mild dysfunction), and EF < 40% (moderate dysfunction) in each liver fibrosis category; C: Total, basal, mid and apical left ventricular wall motion score indexes according to the liver fibrosis categories. EF: Ejection fraction.